甲磺酸溴隐亭
- CAS号:22260-51-1
- 英文名:Bromocriptine mesylate
- 中文名:甲磺酸溴隐亭
- CBNumber:CB4335584
- 分子式:C33H44BrN5O8S
- 分子量:750.7
- MOL File:22260-51-1.mol
- 熔点 :192-196° (dec)
- 比旋光度 :D20 +95° (c = 1 in methanol-methylene chloride)
- 储存条件 :2-8°C
- 溶解度 :H2O: 0.8 mg/mL
- 形态 :solid
- 酸度系数(pKa) :4.90(at 25℃)
- 颜色 :white
- 旋光性 (optical activity) :[α]20/D +95°, c = 1 in methanol: methylene chloride (1:1)(lit.)
- Merck :13,1400
- BRN :4115238
- 稳定性 :Stable for 2 years from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months
- InChIKey :NOJMTMIRQRDZMT-JGYCFGIMSA-N
- CAS 数据库 :22260-51-1(CAS DataBase Reference)
- 危险品标志 :Xn
- 危险类别码 :20/21/22
- 安全说明 :22-24/25-36
- 危险品运输编号 :UN 3077 9 / PGIII
- WGK Germany :3
- RTECS号 :KE1595000
- F :3-10
- 海关编码 :29396900
- 毒性 :LD50 in mice, rats, rabbits (mg/kg): 190, 72, 12.5 i.v. (Parkes)
甲磺酸溴隐亭性质、用途与生产工艺
- 背景 甲磺酸溴隐亭最早由诺华公司开发,主要用于抗震颤麻痹,抑制生理性泌乳和治疗催乳激素过高引起的经前期综合征、肢端肥大症、女性不育症和亨丁顿舞蹈病。临床用于治疗帕金森病,与催乳素有关的生殖系统功能异常,如闭经、溢乳症、经前综合征、产褥期乳腺炎、纤维囊性乳腺瘤、男性阳痿或性欲减退,还可用于垂体腺瘤等。甲磺酸溴隐亭快速释放的口服制剂辅助用于Ⅱ型糖尿病的治疗,该药2009年5月获得FDA批准。
- 作用 本品又称溴麦亭、溴化麦角隐亭、溴克丁、麦角克碱、麦角环肽、抑乳停、甲磺酸溴隐亭,是麦角生物碱的半合成衍生物,能特异地兴奋中枢多巴胺受体,对其他受体有拮抗作用。无麦角类的收缩子宫和血管作用。可抑制PRL、LH的分泌,激活脑内新纹状体的多巴胺受体,控制震颤麻痹综合征;通过中枢或外周的作用松弛血管平滑肌,减低交感神经兴奋性,进而使血压下降,脉率不增加。
- 适应症 适用于治疗高泌乳素血症及泌乳素瘤,或作为泌乳素瘤的术前准备或术后治疗;亦用于治疗垂体生长激素瘤、巨人症及肢端肥大症;或用于垂体促皮质素瘤及库欣(Cushing)病合并血糖升高者的治疗。可用于治疗多囊卵巢综合征,对排卵功能障碍性不孕症有效。对乳腺增生、回乳、月经紊乱、经前紧张综合征、肝性脑病、糖尿病、特发性水肿、垂体性甲亢及甲状腺功能减退症均有一定效果。
-
制备
1)溴隐亭的合成
将α-麦角隐亭12g(20.8mmoL)和二氯甲烷120mL加入反应瓶中,搅拌溶清后依次加入5,5-二溴巴比妥酸3.69g(12.9mmoL)、33%氢溴酸的冰乙酸溶液0.2mL,控温25~30℃反应5~6h,过滤,滤液依次用1moL/L的硫代硫酸钠(30mL),5%的碳酸氢钠溶液(30mL),20%氯化钠溶液(30mL)洗涤。有机相用无水硫酸镁干燥,过滤,并加入硅胶36g浓缩将溶剂完全拉干。柱层析:流动相先为二氯甲烷,后为V(二氯甲烷)∶V(丙酮)=6∶1的混合溶液。得10.6g溴隐亭,收率78%。
2)甲磺酸溴隐亭的合成
将溴隐亭6.0g用二氯甲烷120mL溶清后加入2-丁酮200mL,控制内温20~30℃,加入甲磺酸1.14g,生成结晶型沉淀,搅拌1h。滤出固体,用2-丁酮30mL洗涤,干燥得6.13g甲磺酸溴隐亭,收率86%。
- 生物活性 Bromocriptine mesylate 是一种有效的多巴胺 D2/D3 受体激动剂,结合多巴胺 D2 受体,pKi 为 8.05±0.2。
-
靶点
pKi: 8.05±0.2 (dopamine D2 receptor)
-
体外研究
Bromocriptine stimulates [ 35 S]-GTPγS binding at D2 dopamine receptor expressed in CHO cells with pEC 50 of 8.15±0.05. Bromocriptine also is a strong inhibitor of brain nitric oxide synthase. The ergot alkaloid Bromocriptine (BKT) is found to act as a strong inhibitor of purified neuronal nitric oxide synthase (NOS) (IC 50 =10±2 μM) whereas it is poorly active towards inducible macrophage NOS (IC 50 >100 μM) . Bromocriptine is found to inhibit the activity of at least one human cytochrome P450 enzyme. Bromocriptine is a potent inhibitor of CYP3A4 with a calculated IC 50 value for the interaction of 1.69 μM.
-
体内研究
Bromocriptine mesylate (2 mg/kg, i.p.) is administered for 7 days in groups of mice in forced swimming test (FST) and tail suspension test (TST). Bromocriptine group shows significant anti-immobility action as compared to control. When Bromocriptine administered 30 min after the last dose of 7 days MPE treatment and subjected to FST, this dopaminergic agonist produces significant and dose dependent potentiation of anti-immobility action of MPE (200 mg/kg, p.o.) as compared to MPE treatment alone. Bromocriptine treatment group shows a significant reduction of immobility time as compared to control. Bromocriptine administration after 7 days pretreatment with MPE (100 and 200 mg/kg, p.o.) shows significant and dose dependent potentiation of anti-immobility action of MPE as compared to MPE treatment alone. Intracisternal administration of Bromocriptine decreases significantly the static mechanical allodynia (SMA) score compared to that of sham (saline-injected rats) and its effect lasted for 30 min. Intraperitoneal administration of Bromocriptine induces a significant, dose dependent (0.1 mg and 1 mg/kg) decrease in pain scores in CCI-IoN group when compared to sham and its effect lasted for 6 h. The highest dose induces the highest score decrease (P<0.01). Bromocriptine effect lasts for 20 min. Intraperitoneal administration of Bromocriptine induces a significant dose dependent decrease in SMA score in CCI-IoN+6-OHDA lesioned group compared to that of sham. Its effect lasts for 6 h.
- 类别 有毒物质
- 毒性分级 中毒
- 急性毒性 口服-小鼠 LD50: 2502 毫克/公斤; 静脉-大鼠 LD50: 10.5 毫克/公斤
- 可燃性危险特性 热分解排出有毒氮氧化物,硫氧化物和溴化物烟雾
- 储运特性 库房通风干燥低温
- 灭火剂 水,干粉,二氧化碳,泡沫,沙土
- 更新日期:2024/11/08
- 产品编号:HY-12705A
- 产品名称:Bromocriptine mesylate
- CAS编号:
- 包装:5 mg
- 价格:235元
- 更新日期:2024/11/08
- 产品编号:HY-12705A
- 产品名称:甲磺酸溴隐亭 Bromocriptine mesylate
- CAS编号:22260-51-1
- 包装:10mM * 1mLin DMSO
- 价格:273元
- 公司名称:SIGMA
- 联系电话:--
- 电子邮件:
- 国家:瑞士
- 产品数:6896
- 优势度:91
- 公司名称:AXXORA, LLC
- 联系电话:--
- 电子邮件:alexis-ch@alexis-corp.com
- 国家:瑞士
- 产品数:1104
- 优势度:80
- 公司名称:ALEXIS
- 联系电话:--
- 电子邮件:alexis-ch@alexis-corp.ch
- 国家:瑞士
- 产品数:3599
- 优势度:74
- 甲磺酸培氟沙星 甲基磺酸 溴隐亭 偶氮氯磷 甲磺酸帕珠沙星 伊马替尼 三氟甲磺酸 麦角克碱 溴隐亭杂质E Ergoline-8-carboxylic acid, 2-bromo-9,10-didehydro-6-methyl-, (8β)- BroMocriptine IMpurity F 溴隐亭 -13C-D3 溴隐亭杂质G Ergotaman-3',6',18-trione, 2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-, (2'β,5'α,8α)- (9CI) 麦角隐亭 (8S)-2-BroMo α-Ergocryptine BROMOCRIPTINE IMPURITY A (MIXTURE OF DIASTEREOMERS) 溴隐亭杂质2